



2 April 2019

## **ASX ANNOUNCEMENT**

### **ImpediMed to Become Business Associate-Compliant with Launch of Third-Generation SOZO® Software**

**Carlsbad, CA and Brisbane, Australia – April 2, 2019** – ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that by the end of April 2019, ImpediMed will become Business Associate-compliant and launch third-generation software for its award-winning SOZO Digital Health Platform.

“We are delivering a solution that provides clinical information and analytics even faster in a more secure manner,” says Shashi Tripathi, Chief Technology Officer, ImpediMed. “This will make product development efficient so that we can innovate faster in delivering better value to clinicians.”

He adds that this next generation of software offers a new interface which is easier to navigate, while providing the highest level of security and privacy of patient data in a cloud-based solution. It also offers additional security features for both hospital administrators and clinical users.

ImpediMed has expanded the security in its compliance with the Health Insurance Portability and Accountability Act (HIPAA) and Business Associate by further improving all the controls defined by Health and Human Services (HHS) 45 CFR’s security and privacy rules. This allows them to partner with institutions to collect pertinent patient information during each test.

The new software is taking advantage of artificial intelligence combined with tens of thousands of existing SOZO patient records to simplify and automate the use of the data collected. This will enhance the accuracy of the end results to improve system performance and the user experience.

The new software will be more powerful and significantly streamline the installation and maintenance process by moving all data handling, storage and analysis to a Cloud-based service.

The SOZO Digital Health Platform was launched in 2018 and is currently being used by hospitals and clinics in the United States and globally mainly to aid in the assessment of early detection of secondary lymphoedema in cancer patients and fluid accumulation in heart failure patients for fluid overload. The SOZO Digital Health Platform is a scalable, simple-to-use, non-invasive, highly accurate system providing clinicians with extensive, objective, medically meaningful results in less than 30 seconds.

Richard Carreon, Managing Director and CEO, ImpediMed says, “The functionality and performance of the SOZO platform continues to advance at a rapid pace. This latest software version will allow us to more efficiently and effectively analyze our growing user database to further improve our algorithms, enhance performance and provide real-world clinical data for FDA/CE Mark submissions.”

**Richard Carreon**  
**Managing Director & CEO**

**Media Contact:**

Kyahn Williamson, WE Buchan  
T: +61 3 9866 4722  
E: [kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

**About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).